Nilemdo and Nustendi Win Funding In England For High Cholesterol
NICE Is Also Developing Guidance For Novartis’s Cholesterol-Lowering Leqvio
Around 70,000 adults in England with primary hypercholesterolemia or mixed dyslipidemia will have access to the bempedoic acid ACL inhibitors from Esperion/Daiichi Sankyo.
You may also be interested in...
The innovative collaboration should accelerate access to the first-in-class cholesterol lowering drug acquired with The Medicines Company buy.
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.
Novartis has failed to reach a reimbursement agreement to keep its first-in-class advanced breast cancer drug on the German market, but it is pressing on with plans to expand market access for the product across Europe. It is also working on securing regulatory approval to use Piqray in a broader patient population that would carve out a more meaningful place in the relevant treatment pathway.